AR009358A1 - Compuesto espirociclico inhibidor de la metaloproteasa - Google Patents
Compuesto espirociclico inhibidor de la metaloproteasaInfo
- Publication number
- AR009358A1 AR009358A1 ARP970103899A ARP970103899A AR009358A1 AR 009358 A1 AR009358 A1 AR 009358A1 AR P970103899 A ARP970103899 A AR P970103899A AR P970103899 A ARP970103899 A AR P970103899A AR 009358 A1 AR009358 A1 AR 009358A1
- Authority
- AR
- Argentina
- Prior art keywords
- metalloprotease inhibitor
- spirocyclic compound
- compounds
- pharmaceutical compositions
- metalloprotease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
Abstract
Compuestos de la formula (I), segun se describe en las reivindicaciones, o un isomero, diasteromero o enantiomero optico de los mismos, o una salfarmacéuticamente aceptable, o una amida biohidrolizable, un éster o una imida de los mismos utiles como inhibidores de las metaloproteasas. También sepublican las composiciones y los métodos farmacéuticos para el tratamiento de enfermedades, desordenes y condiciones caracterizadas por la actividadmetaloproteasa usando estos compuestos o las composiciones farmacéuticas que las contienen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2476696P | 1996-08-28 | 1996-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR009358A1 true AR009358A1 (es) | 2000-04-12 |
Family
ID=21822299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970103899A AR009358A1 (es) | 1996-08-28 | 1997-08-27 | Compuesto espirociclico inhibidor de la metaloproteasa |
Country Status (30)
Country | Link |
---|---|
US (1) | US6015912A (es) |
EP (1) | EP0927183B1 (es) |
JP (2) | JP3495376B2 (es) |
KR (1) | KR100326611B1 (es) |
CN (1) | CN1105723C (es) |
AR (1) | AR009358A1 (es) |
AT (1) | ATE272062T1 (es) |
AU (1) | AU736238B2 (es) |
BR (1) | BR9713178A (es) |
CA (1) | CA2264044A1 (es) |
CO (1) | CO4900045A1 (es) |
CZ (1) | CZ63799A3 (es) |
DE (1) | DE69730033T2 (es) |
DK (1) | DK0927183T3 (es) |
ES (1) | ES2225983T3 (es) |
HK (1) | HK1021184A1 (es) |
HU (1) | HUP9904694A3 (es) |
ID (1) | ID19418A (es) |
IL (1) | IL128667A (es) |
NO (1) | NO315373B1 (es) |
NZ (1) | NZ334257A (es) |
PE (1) | PE107798A1 (es) |
PL (1) | PL331920A1 (es) |
PT (1) | PT927183E (es) |
RU (1) | RU2203274C2 (es) |
SK (1) | SK284041B6 (es) |
TR (1) | TR199900429T2 (es) |
TW (1) | TW581761B (es) |
WO (1) | WO1998008850A1 (es) |
ZA (1) | ZA977699B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030206874A1 (en) * | 1996-11-21 | 2003-11-06 | The Proctor & Gamble Company | Promoting whole body health |
HUP0004595A3 (en) | 1997-07-31 | 2001-12-28 | Procter & Gamble | Acyclic metalloprotease inhibitors |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
US6846478B1 (en) | 1998-02-27 | 2005-01-25 | The Procter & Gamble Company | Promoting whole body health |
US6197974B1 (en) * | 1998-10-26 | 2001-03-06 | Abbott Laboratories | Enantioselective synthesis of 3-aminopyrrolidines |
JP2002538136A (ja) | 1999-03-03 | 2002-11-12 | ザ プロクター アンド ギャンブル カンパニー | アルケニルおよびアルキニル含有メタロプロテアーゼ阻害剤 |
HUP0201714A3 (en) | 1999-03-03 | 2003-05-28 | Procter & Gamble | Substituted heterocyclic compounds and pharmaceutical compositions containing them |
MXPA03000043A (es) * | 2000-06-30 | 2003-10-15 | Procter & Gamble | Promocion de la salud en todo el cuerpo. |
DE60134855D1 (de) * | 2000-06-30 | 2008-08-28 | Procter & Gamble | Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen |
US8283135B2 (en) * | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
FR2818643B1 (fr) * | 2000-12-22 | 2003-02-07 | Servier Lab | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques que les contiennent |
WO2003016248A2 (en) | 2001-08-17 | 2003-02-27 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
RU2379303C2 (ru) | 2003-04-24 | 2010-01-20 | Инсайт Корпорейшн | Производные азаспироалканов в качестве ингибиторов металлопротеаз |
DE102004004974A1 (de) * | 2004-01-31 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen |
SG172661A1 (en) * | 2006-06-01 | 2011-07-28 | Sanofi Aventis | Spirocyclic nitriles as protease inhibitors |
US8575208B2 (en) * | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
PL2114951T3 (pl) * | 2007-02-28 | 2014-10-31 | Leo Pharma As | Nowe inhibitory fosfodiesterazy |
SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
RU2523284C9 (ru) * | 2012-05-31 | 2014-10-10 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Способ модификации макролидного антибиотика олигомицина а с помощью реакции [3+2]-диполярного циклоприсоединения азида и алкинов. 33-дезокис-33-(триазол-1-ил)-олигомицины а и их биологическая активность |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
AR110150A1 (es) * | 2016-11-09 | 2019-02-27 | Roivant Sciences Gmbh | Procesos para la preparación de inhibidores de tph1 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6818875A (es) * | 1968-01-24 | 1969-07-28 | ||
US4521537A (en) * | 1982-08-20 | 1985-06-04 | Hoechst-Roussel Pharmaceuticals Incorporated | Spiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine and -3'-pyrrolidine] compounds and their use as antihypertensive agents |
US4555579A (en) * | 1983-03-24 | 1985-11-26 | E. R. Squibb & Sons, Inc. | Dioxolenylmethyl ester prodrugs of phosphinic acid ace inhibitors |
US4709046A (en) * | 1983-05-09 | 1987-11-24 | E. R. Squibb & Sons, Inc. | Acylmercaptoalkanoyl and mercaptoalkanoyl spiro compounds |
EP0189370A3 (de) * | 1985-01-16 | 1988-01-27 | Sandoz Ag | Spiro-dioxolane, -dithiolane und -oxothiolane |
GB8601368D0 (en) * | 1986-01-21 | 1986-02-26 | Ici America Inc | Hydroxamic acids |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
US4847384A (en) * | 1987-03-12 | 1989-07-11 | Sandoz Pharm. Corp. | Process for the preparation of certain nitrogen-containing mono- and bicyclic ace inhibitors, and novel intermediates useful therefor |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB8919251D0 (en) * | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
DD298639A5 (de) * | 1989-12-21 | 1992-03-05 | Institut Fuer Chemische Technologie,De | Verfahren zur herstellung von sulfobetainsubstituierten alpha-sulfonyl-carbonsaeuren aus diallylammoniumsalzen |
DE4011172A1 (de) * | 1990-04-06 | 1991-10-10 | Degussa | Verbindungen zur bekaempfung von pflanzenkrankheiten |
US5183900A (en) * | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
GB9107368D0 (en) * | 1991-04-08 | 1991-05-22 | Smithkline Beecham Plc | Novel compounds |
IL98681A (en) * | 1991-06-30 | 1997-06-10 | Yeda Rehovot And Dev Company L | Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives |
DE4127842A1 (de) * | 1991-08-22 | 1993-02-25 | Rhone Poulenc Rorer Gmbh | 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate |
JPH05125029A (ja) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
FR2689509B1 (fr) * | 1992-04-01 | 1994-06-03 | Adir | Nouveaux derives spiraniques du 3-amino chromane, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
DE69309047T2 (de) * | 1992-04-07 | 1997-09-11 | British Biotech Pharm | Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren |
WO1993021942A2 (en) * | 1992-05-01 | 1993-11-11 | British Biotech Pharmaceuticals Limited | Use of mmp inhibitors |
AU666727B2 (en) * | 1992-06-25 | 1996-02-22 | F. Hoffmann-La Roche Ag | Hydroxamic acid derivatives |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
CA2193691A1 (en) * | 1994-06-22 | 1995-12-28 | Andrew Miller | Metalloproteinase inhibitors |
-
1997
- 1997-08-22 SK SK255-99A patent/SK284041B6/sk unknown
- 1997-08-22 PT PT97939445T patent/PT927183E/pt unknown
- 1997-08-22 IL IL12866797A patent/IL128667A/en not_active IP Right Cessation
- 1997-08-22 KR KR1019997001652A patent/KR100326611B1/ko not_active IP Right Cessation
- 1997-08-22 AU AU41532/97A patent/AU736238B2/en not_active Ceased
- 1997-08-22 EP EP97939445A patent/EP0927183B1/en not_active Expired - Lifetime
- 1997-08-22 DE DE69730033T patent/DE69730033T2/de not_active Expired - Fee Related
- 1997-08-22 CN CN97197542A patent/CN1105723C/zh not_active Expired - Fee Related
- 1997-08-22 ES ES97939445T patent/ES2225983T3/es not_active Expired - Lifetime
- 1997-08-22 RU RU99106587/04A patent/RU2203274C2/ru not_active IP Right Cessation
- 1997-08-22 NZ NZ334257A patent/NZ334257A/xx unknown
- 1997-08-22 DK DK97939445T patent/DK0927183T3/da active
- 1997-08-22 CZ CZ99637A patent/CZ63799A3/cs unknown
- 1997-08-22 CA CA002264044A patent/CA2264044A1/en not_active Abandoned
- 1997-08-22 HU HU9904694A patent/HUP9904694A3/hu unknown
- 1997-08-22 AT AT97939445T patent/ATE272062T1/de not_active IP Right Cessation
- 1997-08-22 BR BR9713178-4A patent/BR9713178A/pt not_active IP Right Cessation
- 1997-08-22 TR TR1999/00429T patent/TR199900429T2/xx unknown
- 1997-08-22 PL PL97331920A patent/PL331920A1/xx unknown
- 1997-08-22 WO PCT/US1997/014557 patent/WO1998008850A1/en not_active Application Discontinuation
- 1997-08-22 JP JP51171798A patent/JP3495376B2/ja not_active Expired - Fee Related
- 1997-08-26 US US08/918,328 patent/US6015912A/en not_active Expired - Fee Related
- 1997-08-27 CO CO97049506A patent/CO4900045A1/es unknown
- 1997-08-27 ZA ZA9707699A patent/ZA977699B/xx unknown
- 1997-08-27 AR ARP970103899A patent/AR009358A1/es unknown
- 1997-08-28 ID IDP972995A patent/ID19418A/id unknown
- 1997-08-28 PE PE1997000769A patent/PE107798A1/es not_active Application Discontinuation
-
1998
- 1998-02-03 TW TW087101299A patent/TW581761B/zh not_active IP Right Cessation
-
1999
- 1999-02-23 NO NO19990856A patent/NO315373B1/no unknown
-
2000
- 2000-01-06 HK HK00100094A patent/HK1021184A1/xx not_active IP Right Cessation
-
2003
- 2003-08-13 JP JP2003292947A patent/JP2004002470A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR009358A1 (es) | Compuesto espirociclico inhibidor de la metaloproteasa | |
AR012264A1 (es) | Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada | |
CO4920240A1 (es) | Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
CO4900036A1 (es) | Compuestos inhibidores de metaloproteasas de amina ciclica substituida composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
CO4920241A1 (es) | Compuestos inhibidores de metaloproteasas heterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
CO4900035A1 (es) | Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion | |
CO4900033A1 (es) | Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas que los contienen . | |
DK0705254T3 (da) | Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer | |
EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
AR001999A1 (es) | Derivados de acido carboxilico y composiciones conteniendolos, utiles como inhibidores de metaloproteasa de matriz, y procesos para su preparacion. | |
AR013477A1 (es) | Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. | |
ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
CY1107473T1 (el) | Ενα παραγωγο pyridine-n-oxide, και διαδικασια για τη μετατροπη του σε αποτελεσματικες φαρμακευτικες συνθεσεις | |
BR9909620A (pt) | Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo | |
PA8426801A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. | |
CO5180578A1 (es) | Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas | |
TR199900401T2 (xx) | Bidentat metaloproteaz inhibit�rleri. | |
CO5011061A1 (es) | Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen | |
BR0109328A (pt) | Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica | |
ES2202156T3 (es) | Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f. | |
BR0109348A (pt) | Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas | |
DK0656001T3 (da) | Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere | |
PE20021016A1 (es) | Conjugados de pregabalina-lactosa | |
NO983511D0 (no) | Difenylstilbener som pro-legemidler for COX-2-inhibitorer | |
ES2174034T3 (es) | Naftilglioxamidas como inhibidores de spla2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |